GIPR and obesity due to melanocortin 4 receptor deficiency: While numerous proof-of-concept candidate molecules have been disclosed (34–43), the only approved example of multi-receptor agonism for obesity and T2D is the dual GLP-1R/GIPR co-agonist tirzepatide (marketed as Mounjaro® and Zepbound®) (34, 44).